Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Garmin

Walgreens

Bitcoin, Walgreens, Elanco Animal Health and Garmin were our top stock trades for Thursday. Let's have a look at what the charts are saying.

4 Top Stock Trades for Friday: Bitcoin, WBA, ELAN, GRMN

Elanco outlined its latest financial targets at a recent investor day event. The innovation engine is in full swing, and if it delivers, I see plenty of upside to the conservative top-line targets.

Elanco Animal Health: Investor Day Highlights Path Toward Closing The Valuation Gap

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 7:30 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT EL

Elanco to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Freshpet

Chewy

Spending on pets is a $100 billion industry. Here's how you can take advantage.

3 Stocks to Profit From the Pet Economy

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today will host its Investor Day, where the executive leadership team will outline the company's strengthened and expanded Innovation, Portfolio, Productivity (IPP) strategy, introduce a long-term growth algorithm for accelerated value creation, and discuss 2020 financial targets and 2021 guidance. "Today offers a transparent look into our business,” said Jeff Simmons, president and chief executive officer at Elan

Elanco Animal Health Hosts Investor Day, Demonstrating Inflection Point Toward Accelerated Value Creation

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NYSE: ELAN shares. Investors, who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) prior to January 2020 and continue to hold any of those NYSE: ELAN shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. A lawsuit was filed on May 20,2020, against Elanco Animal Health Incorporated over alleged Securities Laws Violations. The plaintiff alleges that the defendants failed to disclose to investors that, after consolidating its distributors from eight to four, the Company increased the amount of inventory, including companion animal products, held by each distributor, that Elanco's distributors were not experiencing sufficient demand to sell through the inventory, that, as a result, the Company's revenue was reasonably likely to decline, that, as a result of the foregoing, Elanco would reduce its channel inventory with respect to companion animal products, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.. Those who purchased Elanco Animal Health Incorporated (NYSE: ELAN) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc.  Michael Daniels  +1 (858) 779-1554  mail@shareholdersfoundation.com   3111 Camino Del Rio North  Suite 423  San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Lawsuit for Investors in Elanco Animal Health Incorporated (NYSE: ELAN) shares announced by Shareholders Foundation

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed distinguished healthcare executive, animal health director and investor William F. Doyle to the Board of Directors, effective immediately. Elanco has also expanded the Board and appointed Scott Ferguson, managing partner of Sachem Head Capital Management (Sachem Head), and Paul Herendeen, chief financial officer of Bausch Health, to the Board, effective immediately, and the co

Elanco Appoints New Independent Directors to the Board and Expands Innovation and Operational Oversight

Kindred Biosciences

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus (CPV). This deadly disease impacts at least 250,000 puppies annually in the U.S., according to Banfield Pet Hospital1, with no approved treatment available. Data from BluePearl Specialty and

Elanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to Market

GREENFIELD, Ind.--(BUSINESS WIRE)--After a rigorous multi-state search, Elanco Animal Health, Inc. (NYSE: ELAN) today announced Indiana as its base for future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis. The move represents another step in Elanco's plan to capture economic value through global footprint consolidation after its August acquisition of Bayer's animal health business. The competitive incentive package off

Elanco Animal Health Selects Indiana as Home for Global HQ and Future Footprint Consolidation

Elanco Animal Health, Inc. (ELAN) Presents at Evercore ISI HealthCONx Broker Conference Call - (Transcript)

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it will host a virtual investor day on Tuesday, December 15, 2020. The event will feature presentations from Jeff Simmons, Elanco president and CEO, along with other members of Elanco's executive leadership team. Management will outline its strategy to drive long-term shareholder value while also providing financial guidance for 2021. A live question and answer session will follow the presenta

Elanco to Host Virtual Investor Day, Provide 2021 Guidance

Bayer AG

Elanco Animal Health Inc (NYSE: ELAN) in a filing with the U.S. Securities and Exchange Commission on Monday disclosed that German pharma and life sciences company Bayer AG (OTC: BAYRY) is offloading a substantial stake it holds in Elanco through a public offering and generate $1.6 billion in proceeds. In August this year, Bayer acquired 72.9 million Elanco shares after the sale of Bayer's Animal Health business segment.

Bayer Sells $1.6B Stake In Elanco Animal Health

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the pricing of the previously announced public offering of 54,500,000 shares of its common stock held by Bayer World Investments B.V, an affiliate of Bayer AG, at $30.25 per share. Bayer World Investments B.V. is the sole selling shareholder and has also granted to the underwriters an option to purchase up to an additional 8,175,000 shares of common stock. Elanco will not issue shares in the offeri

Elanco Announces Pricing of Public Offering of Common Stock by Selling Shareholder

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) announced today the launch of a public offering of 54,500,000 shares of its common stock held by Bayer World Investments B.V, an affiliate of Bayer AG. Bayer World Investments B.V. will be the sole selling shareholder and will also grant to the underwriters an option to purchase up to an additional 8,175,000 shares of common stock. Elanco will not issue shares in the offering and will not receive any proceeds from

Elanco Announces Public Offering of Common Stock by Selling Shareholder

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:00 p.m. ET. A live audio webcast will be available on the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately one year. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) is

Elanco to Participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference

Credit Suisse

Elanco Animal Health Incorporated (ELAN) CEO Jeffrey Simmons on Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

Elanco Animal Health Incorporated's (ELAN) CEO Jeff Simmons on Credit Suisse 29th Annual Virtual Healthcare Conference - Quick Version Earnings Call Transcript

Elanco Animal Health Incorporated's (ELAN) CEO Jeffrey Simmons on Q3 2020 Results - Earnings Call Transcript

Elanco Animal Health posted third-quarter earnings that edged views after completing its big Bayer Animal Health acquisition, but its sales and sales guidance lagged views. ELAN stock fell.

Elanco Animal Health Earnings Mixed, Sales Guidance Lags Expectations

  Shares of Elanco Animal Health (NYSE:ELAN) rose 0.1% in pre-market trading after the company reported Q3 results.

Elanco Animal Health: Q3 Earnings Insights

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the third quarter of 2020 and provided guidance for the fourth quarter of 2020. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020. "In the third quarter, Elanco executed with discipline and urgency to deliver on our stated expectations for the quarter, achieving results at the high end of our guidance while bolsteri

Elanco Animal Health Reports Third Quarter 2020 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be available on the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately one year. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) i

Elanco to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--With the U.S. Food and Drug Administration (FDA) approval of Elura™ (capromorelin oral solution), a new prescription medication to manage weight loss in cats with chronic kidney disease (CKD), Elanco Animal Health (NYSE: ELAN) expands its feline offerings while addressing an unmet need in an increasingly common condition as cats age. CKD causes progressive weight loss due to a variety of factors including decreased appetite, malabsorption, and increased energy

Elanco's Elura™ (capromorelin oral solution) Gains U.S. Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced its first sustainability commitments, just two years after becoming an independent company. The decade-long commitments support the SDGs, address societal challenges and underscore Elanco's role in improving the health of animals, which also improves the health of people and the planet. Today, the company is issuing three Healthy Purpose Pledges to drive sustainable change by 2030, including: Prote

Elanco Releases Healthy Purpose™ 2030 Sustainability Commitments to Improve Health of Animals, People and Planet

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (“Elanco”) (NYSE: ELAN) has received a notification of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (“TRC Capital”) to purchase up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock. TRC Capital’s offer price of $26.45 per share is approximately 4.5% lower than the $27.70 closing price per share of Elanco common stock on the

News for Elanco Animal Health Inc Stock (ELAN)